Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK573719 once-daily DPI study in COPD
2011-001645-33Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Trough FEV1 on Treatment Day 85. Started Jun 2011; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-001645-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001645-33.